Efficacy and safety of intravenous valproate for status epilepticus: A systematic review

CNS Drugs

Volumn 28, Issue 7, 2014, Pages 623-639

  Trinka, Eugen ^a,b,c,d   Höfler, Julia ^a,b   Zerbs, Alexander ^a,b   Brigo, Francesco ^e  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Neurosurgical Department Ch Doppler Medical Center   (Austria)

^c UNIVERSITY OF SALZBURG   (Austria)

^d UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^e UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; ETIRACETAM; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; ANTICONVULSIVE AGENT;

ACUTE BRAIN DISEASE; BRAIN DISEASE; COMPARATIVE STUDY; CONFUSION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EEG ABNORMALITY; EPILEPTIC STATE; HUMAN; HYPERAMMONEMIA; HYPOTENSION; INFUSION RATE; LIVER FAILURE; MEDLINE; MORBIDITY; OBSERVATIONAL STUDY; OPEN STUDY; PANCREATITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADULT; AGE; CHILD; INTRAVENOUS DRUG ADMINISTRATION; STATUS EPILEPTICUS;

ADMINISTRATION, INTRAVENOUS; ADULT; AGE FACTORS; ANTICONVULSANTS; CHILD; HUMANS; STATUS EPILEPTICUS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84904753774     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0167-1     Document Type: Review

References (108)

1. Gastaut H. Clinical and electroencephalographical classification of epileptic seizures. Epilepsia. 1970;11:102-13.
2. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia. 1999;40:120-2. (Pubitemid 29031765)
3. Coeytaux A, Jallon P, Galobardes B, Morabia A. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology. 2000;55:693-7.
4. Knake S, Rosenow F, Vescovi M, Oertel WH, Mueller HH, Wirbatz A, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia. 2001;42:714-8. (Pubitemid 32605930)
5. Vignatelli L, Rinaldi R, Galeotti M, de Carolis P, D'Alessandro R. Epidemiology of status epilepticus in a rural area of northern Italy: a 2-year population-based study. Eur J Neurol. 2005;12:897-902. (Pubitemid 41597603)
6. Govoni V, Fallica E, Monetti VC, Guerzoni F, Faggioli R, Casetta I, et al. Incidence of status epilepticus in southern Europe: a population study in the health district of Ferrara, Italy. Eur Neurol. 2008;59:120-6. (Pubitemid 351301253)
7. DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995;12:316-25.
8. Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology. 1998;50:735-41.
9. Rosenow F, Hamer HM, Knake S. The epidemiology of convulsive and nonconvulsive status epilepticus. Epilepsia. 2007;48(Suppl 8):S82-4.
10. Shorvon S, Baulac M, Cross H, Trinka E, Walker M. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia. 2008;49:1277-85. doi:10.1111/j.1528-1167.2008.01706-3.x. (Pubitemid 351991403)
11. Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA. 1983;249:1452-4. (Pubitemid 13158575)
12. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339:792-8. (Pubitemid 28447452)
13. Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345:631-7. Erratum in: N Engl J Med. 2001;345:1860.
14. Silbergleit R, Lowenstein D, Durkalski V, Conwit R, Neurological Emergency Treatment Trials (NETT) Investigators. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia. 2011;52(Suppl 8):S45-7. doi:10.1111/j.1528-1167.2011.03235.x.
15. Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, NETT Investigators, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366:591-600. doi:10.1056/NEJMoa1107494.
16. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59:205-10. (Pubitemid 34240935)
17. Trinka E. What is the relative value of the standard anticonvulsants: Phenytoin and fosphenytoin, phenobarbital, valproate, and levetiracetam? Epilepsia. 2009;50(Suppl 12):S40-3. doi:10.1111/j.1528-1167.2009.02368.x.
18. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51:251-6. doi:10.1111/j.1528- 1167.2009.02323.x.
19. Trinka E. The use of valproate and new antiepileptic drugs in status epilepticus. Epilepsia. 2007;48:2383.
20. Trinka E. What is the evidence to use new intravenous AEDs in status epilepticus? Epilepsia. 2011;52(Suppl 8):S35-8. doi:10.1111/j.1528-1167.2011. 03232.x.
21. Höfler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;52:e148-52. doi:10.1111/j.1600-0404.2008.01097.x.
22. Höfler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013;54:393-404. doi:10.1111/epi.12058.
23. Barnes SE, Bland D, Cole AP, Evans AR. The use of sodium valproate in a case of status epilepticus. Dev Med Child Neurol. 1976;18:236-8.
24. Vajda FJ, Symington GR, Bladin PF. Rectal valproate in intractable status epilepticus. Lancet. 1977;1:359-60. (Pubitemid 8024423)
25. Vajda FJ, Mihaly GW, Miles JL, Donnan GA, Bladin PF. Rectal administration of sodium valproate in status epilepticus. Neurology. 1978;28:897-9. (Pubitemid 8390043)
26. Viani F, Jussi MI, Germano M, Lotti P, Lotti F. Rectal administration of sodium valproate for neonatal and infantile status epilepticus. Dev Med Child Neurol. 1984;26:678-9. (Pubitemid 14002388)
27. Holle LM, Gidal BE, Collins DM. Valproate in status epilepticus. Ann Pharmacother. 1995;29:1042-4.
28. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16:695-714. (Pubitemid 35176854)
29. Giroud M, Gras D, Escousse A, Dumas R, Venaud G. Use of injectable valproic acid in status epilepticus. A pilot study. Drug Investig. 1993;5:154-9. (Pubitemid 23117886)
30. Czapiński P, Terczyński A. Intravenous valproic acid administration in status epilepticus. Neurol Neurochir Pol. 1998;32:11-22.
31. Campistol J, Fernandez A, Ortega J. Status epilepticus in children. Experience with intravenous valproate. Update of treatment guidelines. Rev Neurol. 1999;29:359-65. (Pubitemid 30458890)
32. Katragadda S, Chand Aluri B, Burdette D. Intravenous administration of valproate for status epilepticus in 12 patients. Epilepsia. 2000;41:216 (Abstract).
33. Überall MA, Trollmann R, Wunsiedler U, Wenzel D. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology. 2000;54:2188-9. (Pubitemid 30397234)
34. Naritoku DK. Outcome of status epilepticus treated with intravenous valproic acid. Adv Stud Med. 2001;1:279-80.
35. Rosenow F, Knake S. Intravenöse Valproinsäuretherapie zur Statusbehandlung. In: Krämer G, Walden J, editors. Valproinsäure. Berlin: Springer; 2002.
36. Jha S, Jose M, Patel R. Intravenous sodium valproate in status epilepticus. Neurol India. 2003;51:421-2. (Pubitemid 38016305)
37. Yu KT, Mills S, Thompson N, Cunanan C. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia. 2003;44:724-6. (Pubitemid 36554643)
38. Patel R, Jha S. Intravenous valproate in post-anoxic myoclonic status epilepticus: a report of ten patients. Neurol India. 2004;52:394-6. (Pubitemid 39430209)
39. Limdi NA, Shimpi AV, Faught E, Gomez CR, Burneo JG. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology. 2005;64:353-5.
40. Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus - experience in 102 adult patients. Seizure. 2005;14:164-16.
41. Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology. 2006;67:340-2. (Pubitemid 44313586)
42. Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16:527-32. (Pubitemid 47209244)
43. Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol. 2007;22:1191-7.
44. Narayanan JT, Murthy JM. Nonconvulsive status epilepticus in a neurological intensive care unit: profile in a developing country. Epilepsia. 2007;48:900-6. (Pubitemid 46763419)
45. Olsen KB, Tauboll E, Gjerstad L. Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. Acta Neurol Scand Suppl. 2007;187:51-4. (Pubitemid 46535915)
46. Gilad R, Izkovitz N, Dabby R, Rapoport A, Sadeh M, Weller B, et al. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand. 2008;118:296-300. doi:10.1111/j.1600- 0404.2008.01097.x.
47. Chen L, Feng P, Wang J, Liu L, Zhou D. Intravenous sodium valproate in mainland China for the treatment of diazepam refractory convulsive status epilepticus. J Clin Neurosci. 2009;16:524-6. doi:10.1016/j.jocn.2008.06.007.
48. Tiamkao S, Sawanyawisuth K. Predictors and prognosis of status epilepticus treated with intravenous sodium valproate. Epileptic Disord. 2009;11:228-31. doi:10.1684/epd.2009.0271.
49. Tripathi M, Vibha D, Choudhary N, Prasad K, Srivastava MV, Bhatia R, et al. Management of refractory status epilepticus at a tertiary care centre in a developing country. Seizure. 2010;19:109-11. doi:10.1016/j.seizure.2009.11.007.
50. Kalita J, Nair PP, Misra UK. A clinical, radiological and outcome study of status epilepticus from India. J Neurol. 2010;257:224-9. doi:10.1007/s00415- 009-5298-9.
51. Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia. 2011;52:1292-6. doi:10.1111/j.1528-1167.2011.03056.x.
52. Chen WB, Gao R, Su YY, Zhao JW, Zhang YZ, Wang L, Ren Y, et al. Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. Eur J Neurol. 2011;18:1391-6. doi:10.1111/j.1468-1331.2011.03420.x.
53. Malamiri RA, Ghaempanah M, Khosroshahi N, Nikkhah A, Bavarian B, Ashrafi MR. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol. 2012;16:536-41. doi:10.1016/j.ejpn.2012.01.012.
54. Czapiński P. Retrospective analysis of therapeutic efficacy of various modalities in status epilepticus. Epilepsia. 1998;39:32 (Abstract).
55. Knake S, Vescovi M, Hamer H, Wirbatz A, Rosenow F. Intravenous sodium valproate in the treatment of status epilepticus. Epilepsia. 1999,40:150 (Abstract).
56. Leninger T, Hofnagel A. Nonconvulsive status epilepticus treated with intravenous valproate. Epilepsia. 1999;40:149 (Abstract).
57. Peters C, Pohlman-Eden B. Efficacy and safety of intravenous valproate in status epilepticus. Epilepsia. 1999;40:149-50 (Abstract).
58. Ramsay R, Lowe M, DeToledo J, Cilavizza N, Pryor F. Pharmakokinetics and safety of high dose rapid infusion of IV valproate (Depacon). Neurology. 1999;A523 (Abstract).
59. Short D. Depacon administartion, safety and efficacy in a hospital setting. Epilepsia. 1999;40:226 (Abstract).
60. Olsen K, Tauboll E, Gjerstad L. Intravenous valproate (VPA) is effective in status epilepticus/serial attacks in adults. Epilepsia. 2004;45:260 (Abstract).
61. Price D. Sodium valproate intravenous: report on clinical experience in neurology and neurosurgery. Paris: Sanofi-Aventis; 1986.
62. Brigo F, Storti M, Del Felice A, Fiaschi A, Bongiovanni LG. IV Valproate in generalized convulsive status epilepticus: a systematic review. Eur J Neurol. 2012;19:1180-91. doi:10.1111/j.1468-1331.2011.03606.x.
63. Sheth RD, Gidal BE. Intravenous valproic acid for myoclonic status epilepticus. Neurology. 2000;54:1201. (Pubitemid 30151873)
64. Devinsky O, Leppik I, Willmore LJ, Pellock JM, Dean C, Gates J, et al. Safety of intravenous valproate. Ann Neurol. 1995;38:670-4.
65. Ramsay RE, Cantrell D, Collins SD, Walch JK, Naritoku DK, Cloyd JC, et al. Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy. Epilepsy Res. 2003;52:189-201. (Pubitemid 36106564)
66. Naritoku DK, Mueed S. Intravenous loading of valproate for epilepsy. Clin Neuropharmacol. 1999;22:102-6.
67. Venkataraman V, Wheless JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res. 1999;35:147-53. (Pubitemid 29243046)
68. Wheless JW, Vazquez BR, Kanner AM, Ramsay RE, Morton L, Pellock JM. Rapid infusion with valproate sodium is well tolerated in patients with epilepsy. Neurology. 2004;63:1507-8. (Pubitemid 39426292)
69. Limdi NA, Knowlton RK, Cofield SS, Ver Hoef LW, Paige AL, Dutta S, Faught E. Safety of rapid intravenous loading of valproate. Epilepsia. 2007;48:478-83. (Pubitemid 46365200)
70. DeWolfe JL, Knowlton RC, Beasley MT, Cofield S, Faught E, Limdi NA. Hyperammonemia following intravenous valproate loading. Epilepsy Res. 2009;85:65-71. doi:10.1016/j.eplepsyres.2009.02.012.
71. Morton LD, O'Hara KA, Coots BP, Pellock JM. Safety of rapid intravenous valproate infusion in pediatric patients. Pediatr Neurol. 2007;36:81-3. (Pubitemid 46176558)
72. Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology. 2000;55:722-4.
73. Anderson GD, Lin Y, Temkin NR, Fischer JH, Winn HR. Incidence of intravenous site reactions in neurotrauma patients receiving valproate or phenytoin. Ann Pharmacother. 2000;34:697-702. (Pubitemid 30395766)
74. O'Brien TJ, Cascino GD, So EL, Hanna DR. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology. 1998;51:1034-9. (Pubitemid 28473396)
75. Burneo JG, Anandan JV, Barkley GL. A prospective study of the incidence of the purple glove syndrome. Epilepsia. 2001;42:1156-9. (Pubitemid 32947936)
76. Rossetti AO, Bromfield EB. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005;65:500-501; author reply 500-501.
77. Embacher N, Karner E, Wanschitz J, Beer R, Trinka E. Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus. Eur J Neurol. 2006;13:e5-6. (Pubitemid 44434306)
78. Burneo JG, Limdi N, Kuzniecky RI, Knowlton RC, Mendez M, Lawn N, et al. Neurotoxicity following addition of intravenous valproate to lamotrigine therapy. Neurology. 2003;60:1991-2. (Pubitemid 36736021)
79. White JR, Santos CS. Intravenous valproate associated with significant hypotension in the treatment of status epilepticus. J Child Neurol. 1999;14:822-3. (Pubitemid 30035510)
80. Fernandez-Fernandez FJ, Garcia-Rego J, Garcia-Jimenez A, Sesma P. Hemorrhagic shock and fulminant hepatic failure associated with valproate. An Med Interna. 1995;12:606-8. (Pubitemid 26407816)
81. Larch J, Trinka E. Intravenous valproate - a systematic review of the evidence. Epilepsia. 2006;47(s3):38-9 (Abstract).
82. Trinka E, Dobesberger J. New treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther Adv Neurol Disord. 2009;2:79-91. doi:10.1177/1756285608100460.
83. Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand. 2011;123:137-41. doi:10.1111/j.1600-0404.2010.01423.x.
84. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001;286:821-30. (Pubitemid 33015576)
85. Panagiotou OA, Contopoulos-Ioannidis DG, Ioannidis JP. Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment. BMJ. 2013;346:f707.
86. Tan RY, Neligan A, Shorvon SD. The uncommon causes of status epilepticus: a systematic review. Epilepsy Res. 2010;91:111-22. doi:10.1016/j.eplepsyres. 2010.07.015.
87. Trinka E, Höfler J, Zerbs A. Causes of status epilepticus. Epilepsia. 2012;53(Suppl 4):S127-38. doi:10.1111/j.1528-1167.2012.03622.x.
88. Misra UK, Kalita J, Nair PP. Status epilepticus in central nervous system infections: an experience from a developing country. Am J Med. 2008;121:618-23. (Pubitemid 351876173)
89. Bharucha NE, Raven RH, Nambiar VK. Review of seizures and status epilepticus in HIV and tuberculosis with preliminary view of Bombay hospital experience. Epilepsia. 2009;50(Suppl 12):S64-6. doi:10.1111/j.1528-1167.2009. 02347.x.
90. Singh G. Other central nervous system infections and status epilepticus. Epilepsia. 2009;50(Suppl 12):67-9. doi:10.1111/j.1528-1167.2009.02360.x.
91. Newton CR. Status epilepticus in resource-poor countries. Epilepsia. 2009;50(Suppl 12):S54-5. doi:10.1111/j.1528-1167.2009.02364.x.
92. Limdi NA, Faught E. The safety of rapid valproic acid infusion. Epilepsia. 2000;41:1342-5.
93. Shorvon S. The management of status epilepticus. J Neurol Neurosurg Psychiatry. 2001;70(Suppl 2):II22-27.
94. Hamer HM, Knake S, Schomburg U, Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology. 2000;54:230-2. (Pubitemid 30038768)
95. Vivekanandan S, Nayak SD. Valproate-induced hyperammonemic encephalopathy enhanced by topiramate and phenobarbitone: a case report and an update. Ann Indian Acad Neurol. 2010;13:145-7. doi:10.4103/0972-2327.64638.
96. Chakor RT, Bharote HS. Topiramate-valproate-induced encephalopathy in migraine. Headache. 2012;52:1321-2. doi:10.1111/j.1526-4610.2012.02213.x.
97. Noh Y, Kim DW, Chu K, Lee ST, Jung KH, Moon HJ, Lee SK. Topiramate increases the risk of valproic acid-induced encephalopathy. Epilepsia. 2013;54:e1-4. doi:10.1111/j.1528-1167.2012.03532.x.
98. Blackford MG, Do ST, Enlow TC, Reed MD. Valproic Acid and topiramate induced hyperammonemic encephalopathy in a patient with normal serum carnitine. J Pediatr Pharmacol Ther. 2013;18:128-36. doi:10.5863/1551-6776-18.2.128.
99. Dhamija R, Gavrilova RH, Wirrell EC. Valproate-induced worsening of seizures: clue to underlying diagnosis. J Child Neurol. 2011;26:1319-21. doi:10.1177/0883073811402204.
100. Bialer M. Clinical pharmacology of parenteral use of antiepileptic drugs. Epilepsia. 2007;48(Suppl 8):S46-8.
101. Aldenkamp A, Vigevano F, Arzimanoglou A, Covanis A. Role of valproate across the ages. Treatment of epilepsy in children. Acta Neurol Scand Suppl. 2006;184:1-13. (Pubitemid 43882144)
102. Ben-Menachem E, Schmitz B, Tomson T, Vajda F. Role of valproate across the ages. Treatment of epilepsy in adults. Acta Neurol Scand Suppl. 2006;184:14-27. (Pubitemid 43882145)
103. Trinka E, Shorvon S. The proceedings of the Innsbruck Colloquium on Status Epilepticus. Epilepsia. 2009;50(Suppl 12):S1-2. doi:10.1111/j.1528-1167. 2009.02357.x.
104. Cock HR, ESETT Group. Established status epilepticus treatment trial (ESETT). Epilepsia. 2011;52(Suppl 8):S50-2. doi:10.1111/j.1528-1167.2011.03237. x.
105. Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, Fountain N, et al. The established status epilepticus trial 2013. Epilepsia. 2013;54(Suppl 6):89-92. doi:10.1111/epi.12288.
106. Grosse P, Rüsch L, Schmitz B. Pancreatitis complicating treatment with intravenous valproic acid. J Neurol. 2002;249:484-5. (Pubitemid 34304628)
107. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23:167-74.
108. Strzelczyk A, Knake S, Oertel WH, Rosenow F, Hamer HM. Inpatient treatment costs of status epilepticus in adults in Germany. Seizure. 2013;22:882-5.